{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:20Z","timestamp":1779527360939,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00853-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:19:14Z","timestamp":1776741554000},"page":"813-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Megan E. B.","family":"Clowse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radboud J. E. M.","family":"Dolhain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Finzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"F\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pluma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdev","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Greenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Utturkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao N.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Teil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/acr.22516","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015;67:313\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228\u201333.","journal-title":"Ann Rheum Dis"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/acr.24037","volume":"72","author":"G Bandoli","year":"2020","unstructured":"Bandoli G, Singh N, Strouse J, et al. Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: a mediation analysis of autoimmune conditions and adverse pregnancy outcomes. Arthritis Care Res (Hoboken). 2020;72:256\u201364.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2340\/00015555-2923","volume":"98","author":"G Br\u00f6ms","year":"2018","unstructured":"Br\u00f6ms G, Haerskjold A, Granath F, et al. Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol. 2018;98:728\u201334.","journal-title":"Acta Derm Venereol"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/1346-8138.15658","volume":"48","author":"YH Huang","year":"2021","unstructured":"Huang YH, Yee Ng C, Chiou MJ, et al. Fetal-neonatal and maternal outcomes in women with psoriasis vulgaris: a nationwide population-based registry linkage study in Taiwan. J Dermatol. 2021;48:184\u20139.","journal-title":"J Dermatol"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/1471-0528.15836","volume":"126","author":"K Remaeus","year":"2019","unstructured":"Remaeus K, Stephansson O, Johansson K, et al. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. BJOG. 2019;126:1213\u201322.","journal-title":"BJOG"},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/art.40508","volume":"70","author":"ME Clowse","year":"2018","unstructured":"Clowse ME, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70:1399\u2013407.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"853_CR8","first-page":"S34","volume":"63","author":"AC Eke","year":"2023","unstructured":"Eke AC, Gebreyohannes RD, Fernandes MFS, et al. Physiologic changes during pregnancy and impact on small-molecule drugs, biologic (monoclonal antibody) disposition, and response. J Clin Pharmacol. 2023;63(Suppl 1):S34-s50.","journal-title":"J Clin Pharmacol"},{"key":"853_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109915","volume":"119","author":"MA Tegenge","year":"2023","unstructured":"Tegenge MA, Mahmood I, Struble EB, et al. Pharmacokinetics of antibodies during pregnancy: impact of pregnancy on the pharmacokinetics of antibodies (Part 2). Int Immunopharmacol. 2023;119:109915.","journal-title":"Int Immunopharmacol"},{"key":"853_CR10","first-page":"keae302","volume":"2024","author":"G Alle","year":"2024","unstructured":"Alle G, Guettrot-Imbert G, Larosa M, et al. Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients. Rheumatology. 2024;2024:keae302.","journal-title":"Rheumatology"},{"key":"853_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001036","author":"S Balevic","year":"2024","unstructured":"Balevic S, Sims CA, Eudy A, et al. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease. Lupus Sci Med. 2024. https:\/\/doi.org\/10.1136\/lupus-2023-001036.","journal-title":"Lupus Sci Med"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40262-018-0712-z","volume":"58","author":"SJ Balevic","year":"2019","unstructured":"Balevic SJ, Green TP, Clowse MEB, et al. Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases. Clin Pharmacokinet. 2019;58:525\u201333.","journal-title":"Clin Pharmacokinet"},{"key":"853_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000602","author":"SJ Balevic","year":"2022","unstructured":"Balevic SJ, Weiner D, Clowse MEB, et al. Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. Lupus Sci Med. 2022. https:\/\/doi.org\/10.1136\/lupus-2021-000602.","journal-title":"Lupus Sci Med"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/apt.14040","volume":"45","author":"C Seow","year":"2017","unstructured":"Seow C, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of Infliximab and Adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1329\u201338.","journal-title":"Aliment Pharmacol Ther"},{"key":"853_CR15","unstructured":"U.S. Food and Drug Administration. CIMZIA (Certolizumab Pegol) [Labeling-Package Insert]."},{"key":"853_CR16","unstructured":"European Medicines Agency. Summary of product characteristics (SmPC), Cimzia, INN-certolizumab pegol."},{"key":"853_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5:e000942.","journal-title":"RMD Open"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"A426","DOI":"10.1136\/annrheumdis-2013-eular.1289","volume":"72","author":"T Baker","year":"2013","unstructured":"Baker T, Kevorkian L, Nesbitt A. FRI0162 investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept. Ann Rheum Dis. 2013;72:A426\u2013A426.","journal-title":"Ann Rheum Dis"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, Armstrong-Fisher S, Kopotsha T, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312.","journal-title":"J Reprod Immunol"},{"key":"853_CR21","unstructured":"Clinicaltrials.gov. A study to assess the pharmacokinetics of certolizumab pegol in adults with active rheumatoid arthritis, NCT04740814."},{"key":"853_CR22","unstructured":"Clinicaltrials.gov. A study to test the efficacy and safety of certolizumab pegol in Japanese subjects with moderate to severe chronic psoriasis, NCT03051217."},{"key":"853_CR23","unstructured":"Clinicaltrials.gov. Study to evaluate maintenance of sustained remission of axSpA With CZP compared to placebo (C-OPTIMISE), NCT02505542."},{"key":"853_CR24","first-page":"1","volume":"00","author":"D Menshykau","year":"2024","unstructured":"Menshykau D, Sidhu J, Shaughnessy L, et al. Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases. CPT Pharmacometrics Syst Pharmacol. 2024;00:1\u201311.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1111\/jdv.17486","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Lebwohl M, Sofen H, et al. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021;35:2398\u2013408.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"853_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221087650","volume":"14","author":"M Clowse","year":"2022","unstructured":"Clowse M, Fischer-Betz R, Nelson-Piercy C, et al. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol. Ther Adv Musculoskelet Dis. 2022;14:1759720x221087650.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"853_CR27","unstructured":"Jani M, Isaacs J, Strand V. Immunogenicity in response to biologic agents. The Oxford Textbook of Rheumatoid Arthritis. 2015."},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-017-0535-3","volume":"56","author":"N Vande Casteele","year":"2017","unstructured":"Vande Casteele N, Mould DR, Coarse J, et al. Accounting for pharmacokinetic variability of certolizumab pegol in patients with Crohn\u2019s disease. Clin Pharmacokinet. 2017;56:1513\u201323.","journal-title":"Clin Pharmacokinet"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.491","volume":"55","author":"JR Wade","year":"2015","unstructured":"Wade JR, Parker G, Kosutic G, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn\u2019s disease. J Clin Pharmacol. 2015;55:866\u201374.","journal-title":"J Clin Pharmacol"},{"key":"853_CR30","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00722-0","volume":"24","author":"KL Gill","year":"2022","unstructured":"Gill KL, Jones HM. Opportunities and challenges for PBPK model of mAbs in paediatrics and pregnancy. AAPS J. 2022;24:72.","journal-title":"AAPS J"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"e1129","DOI":"10.1503\/cmaj.202391","volume":"193","author":"A Pham-Huy","year":"2021","unstructured":"Pham-Huy A, Top KA, Constantinescu C, et al. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ. 2021;193:e1129\u201336.","journal-title":"CMAJ"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00853-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:24Z","timestamp":1779525984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00853-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00853-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Megan E. B. Clowse: Grant\/research support from: UCB, GSK. Consultant for: UCB, GSK; Radboud J. E. M. Dolhain: Unrestricted research grants from: Dutch Arthritis Association, ZonMw, UCB and Galapagos. Speaking fees from: UCB, Roche, AbbVie, Genzyme, Novartis, AstraZeneca and Eli Lilly; Stephanie Finzel: Grant\/research support from: Novartis. Consultant for: Novartis, NovoNordisk. Speaker\u2019s honoraria: AbbVie, Chugai, Galapagos, GSK, Novartis, UCB; Frauke F\u00f6rger: Grant\/research support from: UCB. Speaker\u2019s bureau: Mepha, Roche, UCB, MSD; Cornelia Glaser: Speaker\u2019s honoraria: Galapagos, GSK, Pfizer, UCB; Andrea Pluma: Speaker\u2019s honoraria: UCB. Support for attending educational events: Fresenius, UCB. Participation Advisory Board: Galapagos; Laura Shaughnessy, Jagdev Sidhu, Jemma Greenin, Kathy Rice, Joao N. Duarte, Marie Teil: Employee and shareholder of UCB. Gauri Utturkar: Former Employee of UCB; employee of GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CHERISH study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB) (Supplementary Table\u00a04). CHERISH was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Full details of the ethics committee involved are available upon request. All patients provided written informed consent to participate in the study, with the addition of obtaining parental consent where relevant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}